WallStSmart

American Shared Hospital Service (AMS)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 207923% more annual revenue ($60.44B vs $29.05M). AZN leads profitability with a 17.2% profit margin vs -5.3%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AMS

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.0Quality: 4.0
Piotroski: 4/9Altman Z: 0.97

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMSUndervalued (+28.0%)

Margin of Safety

+28.0%

Fair Value

$3.18

Current Price

$1.33

$1.85 discount

UndervaluedFair: $3.18Overvalued
AZNUndervalued (+8.2%)

Margin of Safety

+8.2%

Fair Value

$194.77

Current Price

$185.95

$8.82 discount

UndervaluedFair: $194.77Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMS2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$282.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

AMS4 concerns · Avg: 2.3/10
Market CapQuality
$9.08M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.5%2/10

ROE of -6.5% — below average capital efficiency

EPS GrowthGrowth
-38.1%2/10

Earnings declined 38.1%

Altman Z-ScoreHealth
0.972/10

Distress zone — elevated risk

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMS

The strongest argument for AMS centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bear Case : AMS

The primary concerns for AMS are Market Cap, Return on Equity, EPS Growth.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

AMS profiles as a growth stock while AZN is a mature play — different risk/reward profiles.

AMS carries more volatility with a beta of 0.32 — expect wider price swings.

AMS is growing revenue faster at 15.9% — sustainability is the question.

AZN generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 36/100), backed by strong 17.2% margins and 12.5% revenue growth. AMS offers better value entry with a 28.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Shared Hospital Service

HEALTHCARE · MEDICAL CARE FACILITIES · USA

American Shared Hospital Services rents radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?